134 related articles for article (PubMed ID: 9783932)
1. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
Oefelein MG
J Urol; 1998 Nov; 160(5):1685-8. PubMed ID: 9783932
[TBL] [Abstract][Full Text] [Related]
2. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
3. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
4. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
Meinhardt W; Horenblas S
J Urol; 1999 Jul; 162(1):170-1. PubMed ID: 10379778
[No Abstract] [Full Text] [Related]
5. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
Dearnaley DP; Norman AR; Shahidi M
J Urol; 1999 Jul; 162(1):170. PubMed ID: 10379777
[No Abstract] [Full Text] [Related]
6. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
[TBL] [Abstract][Full Text] [Related]
7. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Pettersson B; Varenhorst E; Petas A; Sandow J
Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
[TBL] [Abstract][Full Text] [Related]
8. [Can serum testosterone level measurement extend the intervals of administration of a long-acting LHRH agonist ?].
Kawamura K
Hinyokika Kiyo; 2010 Jun; 56(6):301-4. PubMed ID: 20610920
[TBL] [Abstract][Full Text] [Related]
9. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
Nejat RJ; Rashid HH; Bagiella E; Katz AE; Benson MC
J Urol; 2000 Dec; 164(6):1891-4. PubMed ID: 11061874
[TBL] [Abstract][Full Text] [Related]
10. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
11. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
12. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
Greil S; Robinson EA; Singal B; Kleer E
Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
[TBL] [Abstract][Full Text] [Related]
13. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
14. Failure to achieve a PSA level Mitchell DM; McAleese J; Park RM; Stewart DP; Stranex S; Eakin RL; Houston RF; O'Sullivan JM
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1467-71. PubMed ID: 17689886
[TBL] [Abstract][Full Text] [Related]
15. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
16. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
[TBL] [Abstract][Full Text] [Related]
17. Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.
Issa MM; Lendvay TS; Bouet R; Young MR; Petros JA; Marshall FF
J Urol; 2005 Sep; 174(3):893-7. PubMed ID: 16093982
[TBL] [Abstract][Full Text] [Related]
18. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
19. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
[TBL] [Abstract][Full Text] [Related]
20. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
